1 |
Endo A, Kuroda M, Tsujita Y. 1976. ML-236A, ML-236B andML-236C, new inhibitors of cholestero genesis produced byPenicillium citrinum. J. Antibiot. 29: 1346-1348
DOI
PUBMED
|
2 |
Masahiko H, Ogawa K, Yoshikawa H. 1993. Morphology study inproduction of ML-236B, a precursor of pravastatin sodium, byPenicillium citrinum. J. Ferment. Bioeng. 76: 470-475
DOI
ScienceOn
|
3 |
Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, BaumerAT, Linz W, Bohm M, Nickenig G. 2002. Cellular antioxidanteffects of atrovastatin in vitro and in vivo. Arteriolscler ThrombVasc Biol. 22: 300-305
DOI
ScienceOn
|
4 |
Dietschy JM, Wilson JD. 1970. Regulation of cholesterol metabolism.N. Engl. J. Med., 282: 1179-1183
DOI
PUBMED
ScienceOn
|
5 |
Tobert JA. 1987. New developments in lipid-lowering therapy :the role of inhibiters of hydroxymethyl-glutaryl-coenzyme Areductase, Circulation, 76(3), 534-538
DOI
PUBMED
ScienceOn
|
6 |
Endo A, and Kuroda M. 1976. Citrinin, an inhibitor of cholesterolsynthesis. J. Antibiotics. 29: 841-843
DOI
PUBMED
|
7 |
Witkin EM. 1976. Ultraviolet mutagenesis and inducible DNArepair in Escherichia coli. Bacteriol. Rev. 40: 869-907
PUBMED
ScienceOn
|
8 |
Nobufusa S, Hosobuchi N, and Yoshikawa H. 1996. Biochemicaland molecular-approaches for production of Pravastatin, a potentcholesterol-lowering drug. Biotech. Ann. Rev. 2; 373-389
DOI
PUBMED
ScienceOn
|
9 |
Miller GL. 1959. Use of dinitrosalicylic acid regent for determinationof reducing Suar. Anal. Chem. 31: 426-428
DOI
|
10 |
Tsujita Y, Kuroda M, Shimada T, Tanzawa K, Arai M, Kaneko I,Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S. 1986.CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase : tissue-selective inhibition of sterol synthesisand hypolipidemic effect on various animal species. Biochim.Biophys. Acta. 877: 50-60
DOI
PUBMED
ScienceOn
|
11 |
Serizawa N, Nakagawa K, Hamano K, Tsujita Y, Terahara A,Kuwano H. 1983. Microbial hydroxylation of ML-236B(compactin)and monacolin K. J. Antibiot. 36: 604-607
DOI
PUBMED
|
12 |
Cleeman JI. 2001. Executive Summary of The Third Report ofThe National Cholesterol Education Program(NCEP) ExpertPanel on Detection, Evaluation, And Treatment of High BloodCholesterol In Adults JAMA. 285(19): 2486-2497
DOI
ScienceOn
|
13 |
Freeman DJ, Norrie J, Sttar N, Neely DG, Cobbe SM, Ford I,Isles C, Lorimer AR, Macfarlane PW, McKillop JH, PackardCJ, Shepherd J, Gaw A. 2001. Pravastatin and the developmentof diabetes mellitus: Evidence for a protective treatment effectin the West of Scotland Coronary Prevention Study. Circulation103: 357-362
DOI
PUBMED
ScienceOn
|
14 |
Hideyuki H, Harumitsu K, Takeshi K, Akira T, Takashi N. 1986.Structure elucidation of bioactive metabolites of ML-236B(Mevastatin)isolated from dog urine. Chem. Pharm. Bull. 34: 1459-1467
DOI
PUBMED
ScienceOn
|
15 |
Kiyoshima K, Takada K, Yamamoto M, Kubo K, Okamoto R,Fukagaway, Ishikura T, Naganawa H, Sawa T, Takeuchi, UmexawaH. 1987. New tylosin anologs produced by mutants ofStreptomyces fradiae. J. Antibiot. 40: 1123-1130
DOI
PUBMED
|
16 |
Stryer L.1995. Biochemistry (4th ed). W.H. Freeman and CompanyVirginia, USA, pp. 685-712
|
17 |
Hosobuchi M, Testsuya S, Masatoshi A, Jo O, Seigo I, Hiroji Y.1992. Production of ML-236B, and inhibitor of 3-hydroxy-3-methylglutaryl Co A reductase, by Penicillium citrinum :Improvements of strain and culture conditions. Biosci. Biotech.Biochem. 57: 1414-1419
DOI
|
18 |
Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S,Takeshima A. 2001. Antiinflammatory and antiarterioscleroticactions of HMG-CoA reductase inhibitor in a rat model ofchronic inhibition of nitric oxide synthesis. Circ. Res. 89: 415-421
DOI
ScienceOn
|
19 |
Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M,Monopoli A, Soldato PD, Ignarro LJ. 2004. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhancedantiproliferative and antiinflammatory properties. Proc. Natl.Acad. Sci. 101: 8497-8502
DOI
ScienceOn
|